1.
Annals of Oncology
; 33(Suppl. 3):S173-S173, 2022.
Article
in English
| GIM | ID: covidwho-2035751
ABSTRACT
Background: COVID-19 pandemic motivated a reorganization of healthcare institutions, which may have led to a negative impact on cancer patients' treatment. This study compared the pathological response (PR) rate to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients who underwent treatment before (BCv) and during (DCv) the COVID-19 pandemic at our institution.